Apple Inc
AAPL
$142.99
(-0.9%)
Alphabet Inc - Class C
GOOG
$99.01
(-0.86%)
Alphabet Inc - Class A
GOOGL
$97.97
(-0.88%)
Amazon.com Inc.
AMZN
$101.95
(-1.17%)
Microsoft Corporation
MSFT
$246.97
(-0.34%)
Meta Platforms Inc - Class A
FB
$196.64
(+0.51%)
Berkshire Hathaway Inc. - Class B
BRK.B
$310.25
(-0.41%)
Alibaba Group Holding Ltd - ADR
BABA
$111.08
(+0.8%)
JPMorgan Chase & Co.
JPM
$140.24
(+0.2%)
Johnson & Johnson
JNJ
$164.26
(+0.51%)
Bank Of America Corp.
BAC
$35.91
(+1.2%)
Exxon Mobil Corp.
XOM
$115.43
(-0.5%)
Wells Fargo & Co.
WFC
$47.26
(+0.82%)
Visa Inc - Class A
V
$228.74
(-0.64%)
Walmart Inc
WMT
$143.81
(-0.04%)
Shell Plc - ADR
RDS.B
$51.06
(0%)
Shell Plc - ADR (Representing Ordinary Shares - Class A)
RDS.A
$51.04
(0%)
Intel Corp.
INTC
$28.35
(+0.3%)
AT&T, Inc.
T
$20.37
(0%)
Unitedhealth Group Inc
UNH
$499.26
(+0.01%)
Cisco Systems, Inc.
CSCO
$48.10
(-1.17%)
PetroChina Co. Ltd. - ADR
PTR
$43.88
(0%)
Novartis AG - ADR
NVS
$87.68
(-3.24%)
Pfizer Inc.
PFE
$43.75
(-0.94%)
Taiwan Semiconductor Manufacturing - ADR
TSM
$93.19
(+0.5%)
No Result
View All Result
The Voice of All
  • Login
  • Home
  • Trend
  • News
    • United Stated
    • Asia
      • Japan
      • Pakistan
      • China
      • India
      • Singapore
    • Europe
      • France
      • Germany
      • Spain
      • United Kingdom
    • Canada
    • Middle East
    • Africa
  • Politics
  • Business
  • Economy
  • Culture
  • Health
  • Lifestyle
  • Sports
  • Tech
  • Videos
  • Travel
  • Blogs
Subscribe
  • Home
  • Trend
  • News
    • United Stated
    • Asia
      • Japan
      • Pakistan
      • China
      • India
      • Singapore
    • Europe
      • France
      • Germany
      • Spain
      • United Kingdom
    • Canada
    • Middle East
    • Africa
  • Politics
  • Business
  • Economy
  • Culture
  • Health
  • Lifestyle
  • Sports
  • Tech
  • Videos
  • Travel
  • Blogs
Subscribe
The Voice of All
No Result
View All Result
Home Health

The BA.2 subvariant of Omicron accounts for over half of new U.S. coronavirus cases, the C.D.C. says.

March 30, 2022
in Health
0 0
A A
0
VIEWS
FacebookTwitterLinkedIn

The highly contagious Omicron subvariant known as BA.2, which led to a surge of coronavirus cases in Europe, is now the dominant version of the virus in new U.S. cases, according to estimates from the Centers for Disease Control and Prevention on Tuesday.

Last week, the World Health Organization reiterated that BA.2 was the dominant version of Omicron around the world, and Dr. Rochelle Walensky, the director of the C.D.C., said she anticipated it would soon become dominant in the United States.

Scientists have been keeping an eye on BA.2, one of three genetically distinct varieties of the Omicron variant of the coronavirus, which was discovered by South African researchers in November.

BA.2 was first identified in the United States in December, and it accounted for about 55 percent of new U.S. cases in the week ending Saturday, according to C.D.C. estimates on Tuesday. The figures are rough estimates subject to revision as more data comes in, as happened in late December, when the agency had to significantly decrease its estimate for the nationwide prevalence of the BA.1 Omicron variant. Before that, the Delta variant had been dominant since July.

Cases of Omicron can only be confirmed by genetic sequencing, which is performed on just a portion of samples across the country. The C.D.C.’s estimates vary in different parts of the country. BA.2 was found in a high proportion of samples in the Northeast, and a lower proportion of samples in the Midwest and Great Plains.

BA.1, which became dominant in late December, was almost entirely responsible for the record-shattering spike in U.S. cases this winter, but earlier this year, BA.2 started to account for a larger proportion of new infections. Its rapid growth is attributed in part to eight mutations in the gene for the spike protein on the virus’s surface, which are not found in BA.1.

While BA.2 is more transmissible than BA.1, it has not been shown to cause more severe illness and vaccines continue to protect against the worst outcomes. Many U.S. health officials have said they expect case numbers to rise without a major surge caused by BA.2, but other scientists worry that the nation isn’t doing enough to prevent another possible surge.

In the U.S., the seven-day average of new cases has dropped significantly from the height of the Omicron BA.1 surge. Though the decrease has slowed in recent days, the average has hovered this past week at about 30,000 cases per day, a level last seen in July, according to a New York Times database.

Covid hospitalizations plummeted in the last two weeks by about 35 percent, to about 18,000 per day. Intensive care unit hospitalizations have fallen, too — by about 42 percent, to under 3,000.

And about 750 coronavirus deaths are being reported each day in the U.S., the lowest daily average since before the Omicron variant took hold late last fall. The last time the rate was this low was in mid-August.

In some European countries, the rise of BA.2 came at the same time as a surge in new cases. In the Asia-Pacific region, Hong Kong, South Korea and New Zealand, all of which suffered relatively little from earlier variants, are now getting walloped by BA.2.

Vaccines continue to protect people against severe disease, especially those who received a booster, experts have repeatedly said.

Source: NY Times

ADVERTISEMENT

Related Posts

Health

Covid Patients Coming Off Ventilators Can Take Weeks to Regain Consciousness

Health

Race Question in Supreme Court Adoption Case Unnerves Tribes

Health

Alcohol Deaths Claim Lives of Working-Age Americans

Health

Big Tobacco Heralds a Healthier World While Fighting Its Arrival

Health

Samuel L. Katz, a Developer of the Measles Vaccine, Dies at 94

Health

Non-stick pans could release millions of microplastic particles in possible ‘health concern,’ study says

Health

Medicare Advantage or Just Medicare?

Health

Alcohol death rate in US is rising, government reports say

Health

Study Shows New Booster Improves Protection for Older People, Pfizer Says

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Trending

    Latest News

    Here’s how ranked-choice voting works.

    Here’s how ranked-choice voting works.

    Jovan Adepo and Thundercat on Jazz, Superheroes and Ego Death

    You’ve Planned the Holiday Menu. Now Where Will You Put All the Guests?

    The Return of the Jaguar

    The Voice of All

    The Voice of All is an online newspaper for cosmopolitans, global entrepreneurs, management staff, influencers, and other modern leaders and everyday people who care about wider aspects and broader opinions.

    Sections

    • Africa
    • Asia
    • Business
    • Canada
    • China
    • Culture
    • Economy
    • Europe
    • France
    • Germany
    • Health
    • India
    • Japan
    • Lifestyle
    • Middle East
    • Pakistan
    • Politics
    • Singapore
    • Spain
    • Sports
    • Tech
    • Travel
    • United Kingdom
    • United Stated
    • Videos

    THE MOST IMPORTANT FINANCE NEWS AND EVENTS OF THE DAY

    Subscribe to our mailing list to receives daily updates direct to your inbox!

    • About
    • Advertise
    • Privacy Policy
    • Terms
    • Contact

    © 2022 All Rights Reserved - The Voice of All

    No Result
    View All Result
    • Home
    • Trend
    • News
      • United Stated
      • Asia
        • Japan
        • Pakistan
        • China
        • India
        • Singapore
      • Europe
        • France
        • Germany
        • Spain
        • United Kingdom
      • Canada
      • Middle East
      • Africa
    • Politics
    • Business
    • Economy
    • Culture
    • Health
    • Lifestyle
    • Sports
    • Tech
    • Videos
    • Travel
    • Blogs

    © 2022 All Rights Reserved - The Voice of All

    Welcome Back!

    Login to your account below

    Forgotten Password?

    Retrieve your password

    Please enter your username or email address to reset your password.

    Log In
    This website uses cookies. By continuing to use this website, you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.